Hadi Clinic, Hawalli, State of Kuwait.
Research Institute of Ophthalmology (RIO), Giza, Arab Republic of Egypt.
J Glaucoma. 2021 Feb 1;30(2):124-128. doi: 10.1097/IJG.0000000000001703.
Deep sclerectomy with intrascleral collagen implant (DSCI) was less effective in lowering intraocular pressure (IOP) than with suprachoroidal implantation. Further studies are needed to establish the potency and safety of deep sclerectomy with suprachoroidal collagen implant (DSSCI).
The purpose of this study was to analyze the safety and IOP-lowering effect of DSSCI in comparison with DSCI.
Geneva University Hospitals, Geneva, Switzerland.
This is a prospective, randomized, controlled study involving 13 patients (26 phakic eyes) with bilateral medically uncontrolled primary or secondary open-angle glaucoma. Bilateral deep sclerectomy was performed with each patient being randomly assigned to receive a collagen implant in the intrascleral space in one eye, and a suprachoroidal collagen implant in the other. Follow-up visits were performed at day 1; at week 1; and at months 6, 9, 12, 18, 30, 48, 54, and 60.
Mean preoperative IOP was 24.1±4.2 mm Hg for DSCI group and 25.3±5.3 mm Hg for DSSCI group (P=0.1). The mean postoperative IOP was 14.8±4.0 mm Hg (DSCI) versus 9.8±3.7 mm Hg (DSSCI) at month 60 (P=0.01). Mean preoperative best-corrected visual acuity for the DSCI group was 0.76±0.22 and 0.74±0.23 for the DSSCI group (P=0.001), while the mean postoperative best-corrected visual acuity was 0.82±0.17 (DSCI) and 0.80±0.17 (DSSCI) at month 60 (P=0.004).
DSSCI demonstrated a greater IOP-lowering effect than deep sclerectomy with intrascleral implantation. The safety profile of both methods was similar. More patients with a longer follow-up are required to comprehensively assess the safety and efficacy of this new approach.
与巩膜下植入相比,深层巩膜切除术联合巩膜内胶原植入(DSCI)降低眼内压(IOP)的效果较差。需要进一步的研究来确定深层巩膜切除术联合巩膜下胶原植入(DSSCI)的效力和安全性。
本研究旨在分析 DSSCI 的安全性和降眼压效果,并与 DSCI 进行比较。
瑞士日内瓦大学医院。
这是一项前瞻性、随机、对照研究,涉及 13 名(26 只未植入人工晶体的眼)双侧药物控制不佳的原发性或继发性开角型青光眼患者。每位患者均行双侧深层巩膜切除术,随机分为一眼巩膜内空间植入胶原,另一眼巩膜下植入胶原。随访时间为术后第 1 天、第 1 周、第 6、9、12、18、30、48、54 和 60 个月。
DSCI 组术前平均眼压为 24.1±4.2mmHg,DSSCI 组为 25.3±5.3mmHg(P=0.1)。DSSCI 组术后 60 个月的平均眼压为 14.8±4.0mmHg,DSCI 组为 9.8±3.7mmHg(P=0.01)。DSCI 组术前最佳矫正视力为 0.76±0.22,DSSCI 组为 0.74±0.23(P=0.001),而术后 60 个月的最佳矫正视力为 0.82±0.17(DSCI)和 0.80±0.17(DSSCI)(P=0.004)。
DSSCI 比深层巩膜切除术联合巩膜内植入物具有更强的降眼压作用。两种方法的安全性相似。需要更多的患者和更长时间的随访来全面评估这种新方法的安全性和有效性。